Goldfinch Bio Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$7.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Goldfinch Bio's estimated annual revenue is currently $8.8M per year.(i)
  • Goldfinch Bio received $55.0M in venture funding in December 2016.
  • Goldfinch Bio's estimated revenue per employee is $155,000
  • Goldfinch Bio's total funding is $7.9M.

Employee Data

  • Goldfinch Bio has 57 Employees.(i)
  • Goldfinch Bio grew their employee count by -16% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Our Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. At Goldfinch, were pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. Were looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.

keywords:N/A

$7.9M

Total Funding

57

Number of Employees

$8.8M

Revenue (est)

-16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Goldfinch Bio News

2022-03-30 - Stay alive': Wave of layoffs crashes into biotech startup inferno

bio, a Boston-area biopharma recruitment and executive search firm that's worked with Rubius Therapeutics, Deciphera, Goldfinch Bio and others.

2022-03-22 - Goldfinch Bio to Host Virtual Event on Unmet Need in Focal ...

Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope...

2022-03-22 - Goldfinch Bio Announces Positive Preliminary Data from ...

Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and...

2020-07-02 - Ally Bridge Portfolio News – Goldfinch Bio Secures $100 Million in Series B Financing

Proceeds Support Advancement of Lead Product Candidates GFB-887 and GFB-024 Through Three Clinical Proof-of-Concept Readouts Oversubscribed Round Includes Public Healthcare Funds CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and d ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A57-7%N/A
#2
$12.9M5710%N/A
#3
$8.8M570%N/A
#4
$16.6M572%N/A
#5
N/A58-31%N/A

Goldfinch Bio Funding

DateAmountRoundLead InvestorsReference
2016-12-15$55.0MAThird Rock Ventures, LLCArticle